The 2002-2003 pandemic of severe acute respiratory syndrome (SARS) posed an enormous threat to global public health and the social and economic stability. Its causative pathogen, the SARS-associated coronavirus (SARS-CoV), has been classified by NIAID as a Category C Priority Pathogen. SARS outbreaks remain a serious concern mainly due to possible zoonotic reintroduction of SARS-CoV into humans, accidental release from a laboratory or deliberate spreading of the virus by a bioterrorist attack. Therefore, an effective and safe vaccine is urgently needed for preventing future SARS outbreaks and for biodefense preparedness. We have identified a highly promising lead candidate vaccine antigen, the receptor binding domain (RBD) of the SARS- CoV spike (S) protein that contains the major neutralizing epitopes and can induce potent neutralizing antibody response and protection in animals against SARS-CoV infection. To rapidly translate our initial proof of concept findings into a solid platform of clinical trials, a consortium of experts was put together consisting of scientists from Baylor College Medicine, the new home of Sabin Vaccine Institute's product development partnership (BCM-Sabin), the New York Blood Center (NYBC) and the University of Texas Medical Branch (UTMB), and in partnership with industrial partners and non-profit organizations.
The specific aims of this application are: (1) Expression, purification and pre-clinical characterization of the recombinant RBD (rRBD) protein as a vaccine candidate. The rRBD protein will be expressed in bacteria and yeast expression systems and one of these expression systems will be selected for subsequent studies based on yields, purity, stability, antigenicity, functionality, immunogenicity, and efficacy of the rRBD protein. The immunization regimens will be optimized and the ability of rRBD protein to induce cross-neutralizing antibody response, cross-protection and long-term immune responses and protection will be assessed. (2) Process development, characterization, formulation and stability profiling. A scalable and reproducible fermentation process for rRBD (10 liter scale) and a purification process using chromatographic technologies will be developed. Reproducibility will be confirmed. The specific product quality assays and vaccine formulations with alum and/or glucopyrranosyl lipid A (GLA), an innate adjuvant, will be developed. These assays and procedures will serve the basis for formal lot release and stability evaluation post-manufacturing. (3) Technology transfer, cGMP Manufacture, GLP toxicology and IND Preparation. The cell bank production, production processes and the formulation technology for the rRBD-based SARS vaccine will be transferred to Walter Reed Army Institute of Research (WRAIR) pilot facility for 60-L scale GMP manufacture, formulation and fill and finish. The clinical lots will be released by Sabin- Texas and following a pre-IND meeting with the U.S. FDA, GLP toxicology will be initiated at Frontier Biosciences, a Maryland-based contractor.

Public Health Relevance

SARS-CoV is the first new human infectious disease agent of this century classified by NIAID as a Category C Priority Pathogen, and SARS outbreaks still remain a serious global concern mainly due to possible zoonotic reintroduction of SARS-CoV into humans or accidental release from a laboratory or deliberate spreading of the virus by a bioterrorist. We have identified a highly promising lead candidate vaccine antigen, the receptor binding domain (RBD) of the SARS-CoV spike (S) protein that can induce potent neutralizing antibody response and protection against SARS-CoV infection. Our objective is to develop a highly effective and safe recombinant RBD-based SARS vaccine that can be used in humans for prevention of future SARS outbreak and for biodefense preparedness.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI098775-04
Application #
8838040
Study Section
Special Emphasis Panel (ZAI1-RGK-M (J2))
Program Officer
Stemmy, Erik J
Project Start
2012-05-04
Project End
2017-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
4
Fiscal Year
2015
Total Cost
$1,165,726
Indirect Cost
$383,031
Name
Baylor College of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Gye, Hyun Jung; Oh, Myung-Joo; Nishizawa, Toyohiko (2018) Lack of nervous necrosis virus (NNV) neutralizing antibodies in convalescent sevenband grouper Hyporthodus septemfasciatus after NNV infection. Vaccine 36:1863-1870
Nyon, Mun Peak; Du, Lanying; Tseng, Chien-Te Kent et al. (2018) Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine 36:1853-1862
Du, Lanying; Yang, Yang; Zhou, Yusen et al. (2017) MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets 21:131-143
Chen, Wen-Hsiang; Chag, Shivali M; Poongavanam, Mohan V et al. (2017) Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. J Pharm Sci 106:1961-1970
Zeng, Lei-Ping; Ge, Xing-Yi; Peng, Cheng et al. (2017) Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci China Life Sci 60:1399-1402
Wang, Yufei; Tai, Wanbo; Yang, Jie et al. (2017) Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother 13:1615-1624
Tai, Wanbo; Wang, Yufei; Fett, Craig A et al. (2017) Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J Virol 91:
Tai, Wanbo; Zhao, Guangyu; Sun, Shihun et al. (2016) A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 499:375-382
Du, Lanying; Tai, Wanbo; Yang, Yang et al. (2016) Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun 7:13473
Du, Lanying; Jiang, Shibo (2015) Middle East respiratory syndrome: current status and future prospects for vaccine development. Expert Opin Biol Ther 15:1647-51

Showing the most recent 10 out of 15 publications